How has investor appetite in health technology evolved throughout the years? In this blog post we examine the total investments by year into this sector to help answer that question. The graph below shows the total number of investors in all deals stacked by quarters.
As the graphic demonstrates, investor activity in health technology has remained steady in recent years. The 5-Year CAGR of healthtech investor activity from 2013 to 2018 is 11%. In addition, the sector has seen a total of 930 investors in all deals through Q2 of this year. This represents 48% of the total investor activity in 2018, and 87% of the investor activity through Q2 in 2018. Taking all these data points together, we can see that investor appetite for health technology deals is levelling off in recent years.
How has the exit activity for health technology developed in the first half of 2019? This blog post explores health technology exit metrics through Q2 2019 and compares them to previous years. The graph below shows the number of health technology exits by year, stacked by quarters.
As the graphic demonstrates, health technology has seen a total of 37 exit events through Q2 of this year. This represents 56% of the total exits in 2018, and 88% of the exits through Q2 in 2018. Some of the exit events in Q2 2019 include Exonics Therapeutics’ acquisition by Vertex Pharmaceuticals, PatientsLikeMe’s acquisition by the UnitedHealth Group, and Beyond Meat’s IPO.
A straight-line projection of the completed exit activity this year would come out to 74 exit events, which exceeds the total exits in 2018 by 12%. On the other hand, a weighted quarterly average projection of 2019 exit activity would come out to 58 exit events, which falls short of the total exits in 2018 by 12%. Therefore, based on the mid-year data, health technology exit activity in 2019 is projected to be relatively equal to the exit activity in 2018.
How is the funding environment shaping up for health technology in 2019? As we pass the mid-year mark, let’s see how the year-to-date metrics compare to the historical trends. The graph below shows health technology total funding by year, stacked by quarters.
As the graphic demonstrates, health technology has amassed $9.4B through Q1 and Q2 of this year. This amount represents 51% of the total funding in 2018, and 105% of the funding through Q2 in 2018. In addition, the top three funding events in Q2 2019 include a $300M round into Impossible Foods, a $205M round into Collective Health, and a $190M round into Zipline.
A straight-line projection of the completed funding this year would result in $18.9B, which is 103% of the total 2018 funding. On the other hand, a weighted quarterly average projection of 2019 funding would result in $19.3B, which exceeds the total 2018 funding by 5%. Therefore, based on the mid-year data, health technology funding in 2019 is projected to surpass the funding in 2018.
As we make our way through Q1 of 2019, let’s look back on 2018 and analyze how exit activity for health technology compares to previous years. The graphic below shows total annual health technology exit events over time.
As the graphic demonstrates, 2018 saw a drop in health technology exit activity compared to the previous year. The 67 exit events in 2018 represent a 9% decrease from the 74 exit events in 2017, which was the highest year on record for exit activity. However, health technology exits are still on a general upward trend, with a 5-year CAGR of 25% from 2013 to 2018. Some of the exit events in 2018 include AveXis’s acquisition by Novartis for $8.7B, Flatiron Health’s acquisition by Roche for $1.9B, and PillPack’s acquisition by Amazon for $1B.